Edesa Biotech Inc
1 day chart
Kickstart your portfolio with a U.S. stock on us
Sign up and fund a new Wall St account and get a full share randomly chosen between GoPro, Dropbox or Nike.
Sign up and fund a new Wall St account and get a full U.S. share.
T&Cs apply
About EDSA
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing ways to treat inflammatory and immune-related diseases. The Company’s clinical pipeline is focused on two therapeutic areas: medical dermatology and respiratory. In medical dermatology, the Company is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase III-ready asset developed for use as a potential therapy for moderate-to-severe chronic allergic contact dermatitis (ACD), a common occupational skin condition. The Company’s advanced respiratory drug candidate is EB05 (paridiprubart), which is being evaluated in a United States government-funded platform study as a treatment for acute respiratory distress syndrome.
Find out what a historical investment in Edesa Biotech Inc would be worth today using our EDSA stock calculator.
$12.25M
-
0.00%
40.66K
$1.77
$1.71
$1.75
$4.49
$1.55
Ready to start your investing journey with Stake?
Open an accountEDSA FAQs
- Sign up with some I.D. and zero paperwork
- Add funds to your account
- Make your first investment in EDSA
This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.
Invest in EDSA
on Stake
Buy EDSA from US$3 brokerage
Invest in 9,500+ U.S. stocks and ETFs
Own a slice of EDSA from only US$10 with fractional shares
